Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Adherence to preventive swallowing exercises for head and neck cancer patients undergoing (chemo)radiotherapy treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Christina Caroline Plaschke
  • Giulia Bertino
  • James A McCaul
  • Juan J Grau
  • Remco de Bree
  • Gregor Sersa
  • Antonio Occhini
  • Ales Groselj
  • Cristobal Langdon
  • Derrek A Heuveling
  • Maja Cemazar
  • Primoz Strojan
  • C Rene Leemans
  • Marco Benazzo
  • Francesca De Terlizzi
  • Irene Wessel
  • Julie Gehl
Vis graf over relationer

AIM: Electrochemotherapy is an effective local treatment for cutaneous tumours and metastases. In this prospective trial, six European institutions investigated electrochemotherapy in recurrent, mucosal head and neck tumours.

PATIENT AND METHODS: Forty-three patients with recurrent mucosal head and neck tumours and no further curative or reasonably effective palliative treatment options were enrolled and treated with electrochemotherapy. Patients were treated in general anaesthesia using intravenous or local injection of bleomycin followed by delivery of electric pulses to the tumour area. Primary end-point was local tumour response. Secondary end-points were safety and toxicity, overall and progression free survival, and quality-of-life.

RESULTS: Thirty-seven patients were evaluable for tumour response, pain score, side-effects and quality of life questionnaires. Six patients were not evaluable due to lost follow-up, disease progression or death before evaluation. Intention to treat analysis revealed an objective response of 56% (complete response 8 (19%), partial response 16 (37%), stable disease 10 (23%), progressive disease 3 (7%), and not evaluable 6 (14%)). Three patients (7%) remained in complete response at 30, 34, and 84 months post-treatment. The treatment procedure was generally well tolerated. Swelling of the mucosa was observed in the first days after treatment. Pain and use of pain medication rose temporarily; fatigue and dysphagia were also noted in the quality of life assessment.

CONCLUSION: Electrochemotherapy can be applied to mucosal head and neck recurrent tumours accessible to the procedure with promising objective response, survival and toxicity profile. Attention should be paid to post-treatment swelling and planning of pain medication. These favourable results indicate that electrochemotherapy could play a role in patients with recurrent head and neck cancer.

OriginalsprogEngelsk
TidsskriftEuropean journal of cancer (Oxford, England : 1990)
Vol/bind87
Sider (fra-til)172-181
Antal sider10
ISSN0959-8049
DOI
StatusUdgivet - dec. 2017

ID: 52573372